CLYM

Conviction 100HealthcareScan · Mon, Aug 10, 2026

CLYM$13.50-3.57%

ResistanceSupportVol 14Insider sell

Vol MA14 1.14M

May 11May 28Jun 16Jul 6Jul 23Aug 10

Climb Bio, Inc.PHARMACEUTICAL PREPARATIONSwww.climbbio.com ↗

Price13.50

Change-3.57%

Gap-1.32%

Rel volume3.08×

Avg volume1.15M

Avg $ vol14.79M

SMA 2012.77

SMA 5012.36

SMA 2007.40

Price vs 50+9.20%

Price vs 200+82.49%

MA stackbullish

50/200 cross—

Supertrendup · 11.13

RSI (14)57

MACD hist0.11

MACD crossbull · 2d

Stoch %K / %D68 / 79

ADX (14)26

+DI / −DI27 / 13

RSI divergence—

MACD divergence—

ATR %+7.18%

ADR %7.72%

52w high14.00

52w low1.61

From 52w high-3.57%

Above 52w low+738.51%

New 52w highNo

SqueezeOn · 3d

Bollinger width20.35%

%B0.78

Donchian pos67.51%

Donchian high14.53

Donchian low11.36

AVWAP (52w high)13.62

vs AVWAP high-0.91%

AVWAP (52w low)7.51

vs AVWAP low+79.87%

OBV trendDown

Chaikin MF (20)-0.00

Today vs 20d3.08×

Avg vol (14d)1.14M

Avg vol (20d)1.15M

Avg $ vol (20d)14.79M

Market cap—

RS 3m (vs SPY)+11.85%

RS 6m (vs SPY)+186.96%

RS line new highNo

Trend template8/8

Technical rank87.2

1 week+14.31%

1 month-3.57%

3 months+18.73%

6 months+148.16%

1 year+703.57%

YTD+260.00%

P/E-13.44

P/B3.36

P/S—

P/FCF-14.75

EPS-0.8800

Div yield—

ROE-24.99%

ROA-24.30%

Debt/Eq—

Current31.45

EV/EBITDA-11.22

Gross margin—

Net margin—

Rev growth—

EPS growth19.01%

Price target23.43

Target upside67.24%

Analyst ratingBuy

Institutional64.54%

Ent. value760.57M

Revenue—

Net income-13.5M

Gross profit—

Free cash flow-54.54M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out57.26M

Employees29

ListedTue, Aug 10, 2021

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA+

Conviction100 / 100

Pattern quality—

Tech rank87.2 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance14.37

Support11.04

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CLYM

All disclosures →

No recent disclosed trades by Congress in CLYM. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CLYM · 8 buys · 2 sells

Insider	Side	Shares	Value	Traded	Filed
Brennan Aoife President and CEO · Common Stock · 2026-06-29	Sell	30.9K	$407K	2026-06-29	2026-06-30
Brennan Aoife President and CEO · Restricted Stock Units · 2026-06-27	Exercise	68.75K	—	2026-06-27	2026-06-30
Brennan Aoife President and CEO · Common Stock · 2026-06-27	Exercise	68.75K	—	2026-06-27	2026-06-30
RA Capital Nexus Fund III, L.P. Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
Drapkin Kimberlee C Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
WILLIAMS DOUGLAS E Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
Thomas Stephen Basil Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
RA CAPITAL MANAGEMENT, L.P. Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
RA Capital Nexus Fund II, L.P. Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
RA Capital Nexus Fund, L.P. Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08

SEC filings

EDGAR filings in CLYM · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.